Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress. Six sites activated in Phase 1/2 STAND study evaluating ST-503 in chronic neuropathic pain.